VBP-926

Phase 2Small molecule

VVeloce BioPharma LLC

VBP-926 is one of 5 small molecule programs targeting Paronychia. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

ParonychiaActive, not recruiting

ParonychiaPhase 2

Active, not recruiting

Competition

Competitive Landscape

9 competitors in Paronychia

#DrugCompanyPhaseTrials

Timolol Maleate

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 3

1 2

Betamethasone Valerate

GSK

Phase 3

1 3

Intralesional Steroid

KKasr El Aini Hospital

Phase 3

1 4

Achromycin V

WWyeth-Lederle Vaccines

Preclinical

1 5

VBP-926

VVeloce BioPharma LLC

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Paronychia1 trial

A Trial to Evaluate the Efficacy and Safety of Two Concentrations of VBP-926 Solution for the Treatment of Chemotherapy-associated Paronychia in Cancer Patients

Completed·VVeloce BioPharma LLC·Phase 2·NCT03207906·102 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for VBP-926. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — VBP-926 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for VBP-926. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Veloce BioPharma LLC company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: VVeloce BioPharma LLC

VBP-926

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Paronychia1 trial

References

Drug Info

Quick Facts

Related News